Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 18:00:00 03/07/2024 BST			5-day change	1st Jan Change
5.22 ^USD	-2.43%		-3.33%	+27.94%

07-01	Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell Small Cap Comp Value Index	CI
07-01	Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 3000 Value Index	CI

SANA BIOTECHNOLOGY, INC. : Other Events (form 8-K)

January 26, 2023 at 09:18 pm

Item 8.01 Other Events.

On January 26, 2023, Sana Biotechnology, Inc. (the "Company") announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application to initiate a first-in-human study of SC291, a CD19-targeted allogeneic CAR T cell therapy that was developed using the Company's hypoimmune platform, in patients with various B-cell malignancies. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Latest news about Sana Biotechnology, Inc.

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell Small Cap Comp Value Index	06-30	CI
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 3000 Value Index	06-30	CI
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Value Index	06-30	CI
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index	06-30	CI
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 3000E Value Index	06-30	CI
Transcript : Sana Biotechnology, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:40 PM	06-10
Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions	05-21	CI
Transcript : Sana Biotechnology, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:00 PM	05-14
Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	04-18	CI
Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	04-08	CI
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	04-08	CI
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	04-08	CI
JMP Securities Adjusts Sana Biotechnology Price Target to $15 From $8, Maintains Market Outperform Rating	03-01	MT
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	03-01	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	03-01	MT
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	02-29	MT
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	02-16	MT
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP	02-13	CI
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	02-12	MT
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	02-12	MT
North American Morning Briefing : Central Bankers -2-	01-17	DJ
HC Wainwright Upgrades Sana Biotechnology to Buy From Neutral, Price Target is $12	01-16	MT

Chart Sana Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.22 USD

Average target price

12.2 USD

Spread / Average Target

+133.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SANA BIOTECHNOLOGY, INC.	+27.94%	1.16B
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+41.02%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research